- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00568906
Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma
April 30, 2019 updated by: Stanford University
This study will help us understand the gene expression profiles of lung cancer.
We will identify genes related to lung cancer development, their growth and metastasis to the lung.
In addition, we will examine the role nicotine in the development and progression of lung tumors of smokers, ex-smokers, non-smokers on supplemental nicotine and non smokers with no exposure to nicotine.
Study Overview
Status
Terminated
Study Type
Observational
Enrollment (Actual)
129
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients who agree to participate in this study will be those who are undergoing wedge resection, lobectomy on pneumonectomy for clinically diagnosed lung carcinoma or metastatic tumors to the lung, or who are undergoing therapeutic or diagnostic thoracentesis for malignant pleural effusion.
Description
Inclusion Criteria:Adults with non small cell lung cancer Exclusion Criteria:NA
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
identify genes related to lung cancer development, their growth and metastasis to the lung.
Time Frame: day one
|
day one
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Daya Upadhyay, Stanford University
- Principal Investigator: Glenn D. Rosen, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2002
Primary Completion (Actual)
November 30, 2010
Study Completion (Actual)
October 1, 2011
Study Registration Dates
First Submitted
December 4, 2007
First Submitted That Met QC Criteria
December 4, 2007
First Posted (Estimate)
December 6, 2007
Study Record Updates
Last Update Posted (Actual)
May 2, 2019
Last Update Submitted That Met QC Criteria
April 30, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma
- Carcinoma, Giant Cell
Other Study ID Numbers
- LUN0011
- 76094 (Other Identifier: Stanford University Alternate IRB Approval Number)
- SU-11062007-807 (Other Identifier: Stanford University)
- 12472 (Stanford IRB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.